CHRS - Coherus BioSciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
20.56
+0.78 (+3.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.78
Open19.75
Bid0.00 x 1000
Ask0.00 x 900
Day's Range19.74 - 21.18
52 Week Range8.32 - 21.18
Volume1,836,281
Avg. Volume888,229
Market Cap1.426B
Beta (3Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-2.75
Earnings DateAug 6, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.60
Trade prices are not sourced from all markets
  • Did Coherus BioSciences's (NASDAQ:CHRS) Share Price Deserve to Gain 29%?
    Simply Wall St.19 hours ago

    Did Coherus BioSciences's (NASDAQ:CHRS) Share Price Deserve to Gain 29%?

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...

  • GlobeNewswire19 hours ago

    Coherus BioSciences Management to Present at Jefferies 2019 Global Healthcare Conference

    REDWOOD CITY, Calif., May 22, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the Jefferies 2019 Global Healthcare.

  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of CHRS earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Coherus BioSciences Inc Earnings Call

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Coherus BioSciences Inc.

    Coherus BioSciences Inc NASDAQ NMS:CHRSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing Bearish sentimentShort interest | NegativeShort interest is moderately high for CHRS with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on May 16. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding CHRS is favorable, with net inflows of $2.35 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Barrons.com10 days ago

    2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

    Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.

  • Coherus BioSciences, Inc. (CHRS) Q1 2019 Earnings Call Transcript
    Motley Fool13 days ago

    Coherus BioSciences, Inc. (CHRS) Q1 2019 Earnings Call Transcript

    CHRS earnings call for the period ending March 31, 2019.

  • Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue Estimates
    Zacks13 days ago

    Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue Estimates

    Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    Coherus BioSciences: 1Q Earnings Snapshot

    The Redwood City, California-based company said it had a loss of 29 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire14 days ago

    Coherus BioSciences Reports Corporate Highlights and First Quarter 2019 Financial Results

    REDWOOD CITY, Calif., May 09, 2019 -- Coherus BioSciences, Inc. (“Coherus” or “the Company”, Nasdaq: CHRS), today reviewed corporate highlights and reported financial results.

  • Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?
    Insider Monkey15 days ago

    Did Hedge Funds Drop The Ball On Coherus Biosciences Inc (CHRS) ?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • GlobeNewswire20 days ago

    Coherus BioSciences and Amgen Settle Trade Secrets Action

    Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that Amgen and Coherus have settled the trade secret action brought by Amgen against Coherus that was pending in the Superior Court of California County of Ventura. The details of the settlement are confidential but Coherus will continue to market UDENYCA® and will pay a mid-single digit royalty to Amgen for five years. As announced, Coherus will host a conference call on Thursday, May 9, 2019 starting at 4:30 p.m. ET to provide first quarter 2019 financial results and provide a general business update.

  • GlobeNewswire21 days ago

    Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

    REDWOOD CITY, Calif., May 02, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare.

  • Moving Average Crossover Alert: Coherus BioSciences
    Zacks27 days ago

    Moving Average Crossover Alert: Coherus BioSciences

    Coherus BioSciences is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
    Zacks28 days ago

    The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

    The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences

  • 5 Biotech Stocks Defying the Medicare-for-All Scare
    Zacks29 days ago

    5 Biotech Stocks Defying the Medicare-for-All Scare

    Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.

  • GlobeNewswirelast month

    Coherus BioSciences Announces New Employment Inducement Grants

    REDWOOD CITY, Calif., April 19, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective April 18, 2019, the compensation committee of the company’s.

  • Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
    Zackslast month

    Coherus (CHRS) Catches Eye: Stock Jumps 6.9%

    Coherus (CHRS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today
    Motley Foollast month

    Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today

    Guess which of these stocks could see big changes ahead.

  • Here's Why Coherus BioSciences Popped Today
    Motley Foollast month

    Here's Why Coherus BioSciences Popped Today

    The biosimilar leader announced preliminary sales data for its most important product.

  • Read This Before Buying Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares
    Simply Wall St.2 months ago

    Read This Before Buying Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip sid...

  • GlobeNewswire2 months ago

    Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA™ Net Sales

    Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ expectations regarding the continued adoption of UDENYCA™ in the U.S., estimation of channel mix, returns, chargebacks and rebates, each of which impact net sales computation. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. All forward-looking statements contained in this press release speak only as of the date on which they were made.

  • GlobeNewswire2 months ago

    Coherus BioSciences to Report First Quarter Financial Results on May 9th

    REDWOOD CITY, Calif., April 05, 2019 -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2019 financial results will be released.

  • GlobeNewswire2 months ago

    Coherus BioSciences Management to Present at H.C. Wainwright & Co. Global Life Sciences Conference

    REDWOOD CITY, Calif., March 28, 2019 -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the H.C. Wainwright & Co. Global.